In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores...
Source LinkIn late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.